Obesity Featured Articles

  1. How The FDA, MHRA, & EMA Differ On Externally Controlled Trials 10/23/2025

    As the FDA, MHRA, and EMA release draft frameworks on externally controlled trials, sponsors face differing expectations. The U.K. leans pragmatic, the U.S. remains cautious, and Europe’s guidance is still evolving — leaving global trial planners to navigate regulatory gray zones.

  2. Continuous Evidence Generation — Including RWE — Remains Critical To Vaccine Development 10/23/2025

    President of Takeda's Global Vaccine Business Unit Derek Wallace discusses the importance of continuous, real-world data collection in the context of vaccine development in low- and middle-income countries.

  3. How Redefining The Diagnostic Odyssey Can Lead To Better Patient Outcomes 10/22/2025

    Patient advocate Wendy Cogan calls for improved diagnostic pathways as a means to better clinical trial recruitment and design while telling the journey of her late husband's journey to a corticobasal degeneration(CBD)-frontal behavioral-spatial syndrome (FBS) diagnosis.

  4. Clinical Trials At A Crossroads 10/22/2025

    At DPHARM 2025, McKinsey’s Gaurav Agrawal warned that while clinical science is accelerating, trial operations aren’t keeping pace. He outlined a vision for 2035 built on scaling AI, expanding site ecosystems, and bringing trials closer to everyday patient care.

  5. Precision Recruitment: Fixing The Future Of Clinical Trials 10/21/2025

    Explore how to design ethical, effective, and patient-centric AI-powered recruitment pipelines that truly connect the right patients to the right trials.

  6. The Hidden Cost Of Preferred Vendors 10/21/2025

    Familiar vendors offer comfort — but at the cost of innovation, fit, and fresh thinking. Ease shouldn’t outweigh excellence when selecting partners for your clinical trial.

  7. Navigating Biases In Clinical Trial Vendor Selection 10/21/2025

    Biases, often hidden, can distort vendor selection decisions. Recognizing and addressing them across individuals and teams leads to more objective, aligned, and successful clinical trial outcomes.

  8. The Vendor Selection Blunder: An Expensive Oversight In Clinical Trials 10/21/2025

    Vendor selection isn’t just procedural — it shapes trial outcomes. Even with a solid process, missteps can ripple through timelines, budgets, and team morale. Choose wisely.

  9. The 5 Dysfunctions Of Clinical Trial Vendor Selection — And How To Overcome Them 10/21/2025

    Vendor selection often fails due to five common dysfunctions. Identifying and addressing them early improves alignment, trust, and trial performance—avoiding costly delays.

  10. Reframing Vendor Selection: Beyond Price And Past Relationships 10/21/2025

    An RFP is more than a budget tool — it’s a strategic communication document that guides vendors, clarifies expectations, and enables informed, data-driven sponsor decisions.